Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate.
Humans
Male
Prostatic Neoplasms
/ pathology
Feasibility Studies
Cell Adhesion Molecules
/ metabolism
Retrospective Studies
Receptor, ErbB-2
/ metabolism
Aged
Immunoconjugates
/ therapeutic use
Middle Aged
Antigens, Neoplasm
/ metabolism
Membrane Cofactor Protein
/ metabolism
Carcinoma, Ductal
/ metabolism
Aged, 80 and over
CD46
Ductal adenocarcinoma
HER2
Intraductal carcinoma of the prostate
TROP-2
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
02
03
2024
accepted:
03
06
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
Ductal Adenocarcinoma (DAC) and Intraductal Carcinoma of the Prostate (IDC-P) respond poorly to all the currently available conventional therapies. Given their accurate and efficient elimination of cancer cells, Antibody-Drug Conjugates (ADCs) have become one of the most promising anticancer treatments. However, no ADCs have so far been approved for Prostate Cancer (PCa) treatment. This study investigated TROP-2, HER2, and CD46 expression in DAC/IDC-P samples, indirectly analyzing their preliminary feasibility as therapeutic targets for future treatment of the two conditions. We conducted a retrospective study involving 184 participants (87 DAC/IDC-P patients and 97 Prostatic Acinar Adenocarcinoma (PAC) patients with a Gleason score ≥ 8) without prior treatment between August 2017 and August 2022. Immunohistochemical staining was employed to detect the differential protein expressions of TROP-2, HER2, and CD46 in DAC/IDC-P, PAC, and normal prostate tissues. Compared to pure PAC tissues, TROP-2 expression was significantly higher in DAC/IDC-P and DAC/IDC-P-adjacent PAC tissues (H-score 68.8 vs. 43.8, p < 0.001, and 59.8 vs. 43.8, p = 0.022, respectively). No significant differences in HER2 expression were observed across different cancer tissues. Compared to both DAC/IDC-P-adjacent PAC and pure PAC tissues, CD46 expression was significantly higher in DAC/IDC-P tissues (42.3 vs. 28.6, p = 0.041, and 42.3 vs. 24.3, p = 0.0035, respectively). Herein, TROP-2 and CD46 expression was higher in DAC/IDC-P tissues than in pure PAC and normal prostate tissues. This finding implies that ADCs targeting the two proteins hold significant promise as potential future treatments for DAC/IDC-P.
Sections du résumé
BACKGROUND
BACKGROUND
Ductal Adenocarcinoma (DAC) and Intraductal Carcinoma of the Prostate (IDC-P) respond poorly to all the currently available conventional therapies. Given their accurate and efficient elimination of cancer cells, Antibody-Drug Conjugates (ADCs) have become one of the most promising anticancer treatments. However, no ADCs have so far been approved for Prostate Cancer (PCa) treatment. This study investigated TROP-2, HER2, and CD46 expression in DAC/IDC-P samples, indirectly analyzing their preliminary feasibility as therapeutic targets for future treatment of the two conditions.
PATIENTS AND METHODS
METHODS
We conducted a retrospective study involving 184 participants (87 DAC/IDC-P patients and 97 Prostatic Acinar Adenocarcinoma (PAC) patients with a Gleason score ≥ 8) without prior treatment between August 2017 and August 2022. Immunohistochemical staining was employed to detect the differential protein expressions of TROP-2, HER2, and CD46 in DAC/IDC-P, PAC, and normal prostate tissues.
RESULTS
RESULTS
Compared to pure PAC tissues, TROP-2 expression was significantly higher in DAC/IDC-P and DAC/IDC-P-adjacent PAC tissues (H-score 68.8 vs. 43.8, p < 0.001, and 59.8 vs. 43.8, p = 0.022, respectively). No significant differences in HER2 expression were observed across different cancer tissues. Compared to both DAC/IDC-P-adjacent PAC and pure PAC tissues, CD46 expression was significantly higher in DAC/IDC-P tissues (42.3 vs. 28.6, p = 0.041, and 42.3 vs. 24.3, p = 0.0035, respectively).
CONCLUSIONS
CONCLUSIONS
Herein, TROP-2 and CD46 expression was higher in DAC/IDC-P tissues than in pure PAC and normal prostate tissues. This finding implies that ADCs targeting the two proteins hold significant promise as potential future treatments for DAC/IDC-P.
Identifiants
pubmed: 38990246
doi: 10.1007/s00345-024-05109-8
pii: 10.1007/s00345-024-05109-8
doi:
Substances chimiques
TACSTD2 protein, human
0
Cell Adhesion Molecules
0
Receptor, ErbB-2
EC 2.7.10.1
Immunoconjugates
0
ERBB2 protein, human
EC 2.7.10.1
Antigens, Neoplasm
0
Membrane Cofactor Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
404Subventions
Organisme : Key Research and Development Program of Hunan Province of China
ID : 2021SK2014
Organisme : National Natural Science Foundation of China
ID : 82272907
Organisme : National Natural Science Foundation of China
ID : 81974397
Organisme : Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases
ID : XIANGYA; 2022LNJJ13
Organisme : Outstanding Youth Fund Project of Hunan Province
ID : 2024JJ2090
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209
doi: 10.3322/caac.21660
pubmed: 33538338
Ranasinghe W, Shapiro DD, Zhang M et al (2021) Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18:337
doi: 10.1038/s41585-021-00447-3
pubmed: 33824525
Porter LH, Lawrence MG, Ilic D et al (2017) Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol 72:492
doi: 10.1016/j.eururo.2017.03.013
pubmed: 28342640
Jang WS, Shin SJ, Yoon CY et al (2017) Prognostic significance of the proportion of Ductal Component in Ductal Adenocarcinoma of the prostate. J Urol 197:1048
doi: 10.1016/j.juro.2016.11.104
pubmed: 27916712
Harkin T, Elhage O, Chandra A et al (2019) High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU Int 124:907
doi: 10.1111/bju.14831
pubmed: 31136054
Seipel AH, Wiklund F, Wiklund NP et al (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462:429
doi: 10.1007/s00428-013-1385-5
pubmed: 23443941
Ranasinghe W, Shapiro DD, Hwang H et al (2021) Ductal prostate cancers demonstrate poor outcomes with conventional therapies. Eur Urol 79:298
doi: 10.1016/j.eururo.2020.11.015
pubmed: 33279304
Petrylak DP, Vogelzang NJ, Chatta K et al (2020) PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study. Prostate 80:99
doi: 10.1002/pros.23922
pubmed: 31742767
Abel ML, Takahashi N, Peer C et al (2023) Targeting replication stress and chemotherapy resistance with a combination of Sacituzumab Govitecan and Berzosertib: A Phase I clinical trial. Clin Cancer Res 29:3603
doi: 10.1158/1078-0432.CCR-23-0536
pubmed: 37227187
pmcid: 10524218
Vaishampayan UN, Thakur A, Chen W et al (2023) Phase II trial of Pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin Cancer Res 29:122
doi: 10.1158/1078-0432.CCR-22-1601
pubmed: 36255393
pmcid: 9812860
Su Y, Liu Y, Behrens CR et al (2018) Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight 3
Rosellini M, Santoni M, Mollica V et al (2021) Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci 22
Mjaess G, Aoun F, Rassy E et al (2023) Antibody-drug conjugates in prostate cancer: where are we? Clin Genitourin Cancer 21:171
doi: 10.1016/j.clgc.2022.07.009
pubmed: 35999150
Wang X, Zhou L, Qi L et al (2023) High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate. Prostate Cancer Prostatic Dis
Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787
doi: 10.1111/j.1365-2559.2006.02412.x
pubmed: 16722926
Trerotola M, Jernigan DL, Liu Q et al (2013) Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions. Cancer Res 73:3155
doi: 10.1158/0008-5472.CAN-12-3266
pubmed: 23536555
pmcid: 3655712
Remšík J, Binó L, Kahounová Z et al (2018) Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition. Carcinogenesis 39:1411
doi: 10.1093/carcin/bgy095
pubmed: 30010814
Shen M, Liu S, Stoyanova T (2021) The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol 9:73
pubmed: 33816696
pmcid: 8012837
Sperger JM, Helzer KT, Stahlfeld CN et al (2023) Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res 29:2324
doi: 10.1158/1078-0432.CCR-22-1305
pubmed: 36939530
pmcid: 10261916
Jorda M, Morales A, Ghorab Z et al (2002) Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 168:1412
doi: 10.1016/S0022-5347(05)64462-X
pubmed: 12352406
Koeppen HK, Wright BD, Burt AD et al (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38:96
doi: 10.1046/j.1365-2559.2001.01084.x
pubmed: 11207822
Edwards J, Mukherjee R, Munro AF et al (2004) HER2 and COX2 expression in human prostate cancer. Eur J Cancer 40:50
doi: 10.1016/j.ejca.2003.08.010
pubmed: 14687789
Day KC, Hiles L, Kozminsky G (2017) HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 77:74
doi: 10.1158/0008-5472.CAN-16-1656
pubmed: 27793843
Minner S, Jessen B, Stiedenroth L et al (2010) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16:1553
doi: 10.1158/1078-0432.CCR-09-2546
pubmed: 20179235
Nishio Y, Yamada Y, Kokubo H et al (2006) Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68:110
doi: 10.1016/j.urology.2006.01.060
pubmed: 16806433
Wang S, Li J, Hua J et al (2021) Molecular imaging of prostate cancer targeting CD46 using ImmunoPET. Clin Cancer Res 27:1305
doi: 10.1158/1078-0432.CCR-20-3310
pubmed: 33293372
Li J, Huang T, Hua J et al (2023) CD46 targeted (212)pb alpha particle radioimmunotherapy for prostate cancer treatment. J Exp Clin Cancer Res 42:61
doi: 10.1186/s13046-023-02636-x
pubmed: 36906664
pmcid: 10007843
Bidkar AP, Wang S, Bobba KN et al (1916) Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res 29:2023
Weisser NE, Sanches M, Escobar-Cabrera E et al (2023) An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun 14:1394
doi: 10.1038/s41467-023-37029-3
pubmed: 36914633
pmcid: 10011572
Chen L, Mooso BA, Jathal MK et al (2011) Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17:6218
doi: 10.1158/1078-0432.CCR-11-1548
pubmed: 21844010
pmcid: 3186857